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infection;
Guidelinesto a classic primary complex that consists of a cutaneous nodule at the site of injection and
subclinical involvement of the regional lymph nodes, which is self-limiting and requires no
treatment.
However, ipsilateral regional lymph node enlargement may follow BCG vaccine and is consid-
ered as the most common complication, some progress to suppuration. Rarely a disseminated
BCG infection may develop in immunocompromised individuals resulting in a devastating
outcome. Within the last decades, variable strategies have been applied in treating lymphad-
enitis related to BCG vaccine, ranging from observation, anti-mycobacterial therapy, aspira-
tion, incision and drainage to lymph node surgical excision.
We are presenting these guidelines that intended to optimize and standardize management
of various types of BCG related lymph adenitis in children. They are based upon the best avail-
able evidence in literature beside our experience in this field.
Copyright ª 2015, King Faisal Specialist Hospital & Research Centre (General Organization),
Saudi Arabia. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Purpose of the guidelines
To standardize a clinical practice for classification and
management of BCG related lymphadenitis in children,
extrapolated from the relevant literature besides our
accumulative experience in this field, through evaluation
of benefits and harms of alternative care options. These
guidelines intended to provide an outcome with maximum
benefits and minimum risks, reduce the inappropriate
variation in clinical practice, eliminate the unnecessary
interventions, promote efficient use of resources and
support the decision making processes for the best inter-
est of children presenting with BCG related
lymphadenitis.
2. Introduction
BCG vaccine developed by Albert Calmette and Camille
Guerin in France between 1908 and 1921 contained a live
attenuated Mycobacterium bovis. Currently, there are
multiple strains of BCG vaccines in use around the world
produced by different manufacturers.
BCG is now used worldwide in childhood immunization
programs with approximately 100 million newborns being
vaccinated each year [1]. In Saudi Arabia, BCG was intro-
duced initially for population at risks in 1964 and later for
all newborns in 1970 [2].
Efficacies of BCG vaccines ranges from 0 to 80% in
studies of different populations throughout the world [3].
The main role of the BCG vaccines is to protect vaccinees,
especially infants and children against disseminated TB and
tuberculous meningitis with an estimated efficacy of 78%
and 64% respectively [4,5]. The current estimated inci-
dence of TB in Saudi Arabia is 14/100,000 [6]. Globally the
incidence of BCG adverse reaction differs between regions,
ranging between 0.5e100 per 1000 vaccinations [7e9] with
the most common presentation is regional lymphadenitis,
mainly non-suppuartive lymphadenitis. A rare complicationis a disseminated disease, in less than one in a million of
vaccinated individuals [7,10].
In Saudi Arabia, a raised incidence in BCG related
lymphadenitis from zero to 10.4 per 1000 vaccinations was
linked to the introduction of the Danish strain(SSI 1331),
currently in use since November 2005 [11], leading to more
awareness about this complication [12] and raising the need
to establish national guidelines with the best management
approach and outcome.
3. Classification of BCG related lymphadenitis
The term BCG lymphadenitis applies when lymph node(s)
have become large enough to be easily palpable and a
cause of concern for the parents [13,14], likely with a
diameter greater than or equal to 1 cm.
3.1. Regional BCG related lymphadenitis
The term regional lymphadenitis may apply when there is a
BCG vaccine at one arm with ipsilateral regional lymph
node(s) involvement. Laboratory and radiological in-
vestigations are not routinely recommended in a thriving
child with unremarkable physical examination and no evi-
dence of immunodeficiency in the family history.
The flowing features are in favor of regional BCG related
lymphadenitis rather than other pathology [14e16]:
1) BCG vaccination at the ipsilateral arm.
2) Onset between 2 weeks and 6 months, most patients
present within 2e4 months after BCG vaccination.
3) Child age not more than 2 years
4) Absence of systemic manifestations such as fever and
weight loss.
5) Absence of tenderness over the lymph node(s).
6) Axillary lymph node is mostly involved, although supra-
clavicular or cervical may be involved in isolation or
association with axillary lymphadenopathy.
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lymphadenopathy or organomegaly.3.1.1. Non suppurative lymphadenitis
This form represents the majority of BCG related
lymphadenitis.
Its typically develops 2 weeks to 6 months post immu-
nization and tends to affect the axillary lymph node(s).
Supraclavicular and cervical lymph nodes can be involved,
in isolation or in addition to the axillary lymph node(s)
[17,18], usually it regress with time and some may progress
to suppuration.
3.1.2. Suppurative lymphadenitis
The suppurative form is marked by the progressive
enlargement of regional lymph node(s) with collection of
suppurative material and fluctuation associated with ery-
thema and edema. If untreated, suppurative lymphadenitis
frequently ruptures with sinus formation, resulting in pro-
longed course of illness and scaring sequels [14,15].
3.2. Disseminated BCG infectio
The term disseminated BCG infection considered when
there is involvement of distant anatomical site(s) beyond
BCG administration site and ipsilateral lymph node(s) [19].
Synonyms of disseminated BCG infection are disseminated/
systemic BCG disease or BCGosis.
Disseminated BCG infection is the most serious compli-
cation of BCG vaccination. Fatal infection has occurred at a
rate of 0.06e1.56 cases per million doses [12]; these deaths
occurred primarily among immunocompromised persons.
Immune response to Mycobacterial infection starts with
macrophages through phagocytosis and followed by cell
mediated immunity. A granuloma formation is associated
with production of chemokines and cytokines. Both tumor
necrosis factor (TNF) and interferon gamma (IFN-g) are the
cornerstone cytokines involved in activation of macrophage
host defense mechanisms [1].
The disseminated BCG infection has been reported in
immunocompromised children with primary immunodefi-
ciency (PID), including severe combined immunodeficiency
(SCID) [12,20], complete Di George syndrome (cDGS),
chronic granulomatous diseases (CGD), the Mendelian sus-
ceptibility to mycobacterial disease (MSMD) (e.g. IFN-g re-
ceptor 1/2 deficiencies, IL-12/23 receptor b1 chain
deficiency, IL-12p40 deficiency, S TAT1 deficiency and
NEMO deficiency and acquired immune deficiency syndrome
(AIDS) [12,21].
3.2.1. Clinical presentation of disseminated BCG
infection
The following findings may indicate disseminated BCG
infection:
1) Systemic manifestations: fever, anemia, loss or poor
weight gain.
2) Distant lymph node(s) enlargement, beyond the ipsilat-
eral lymph node(s) such as right axillary or inguinal.3) Cutaneous lesions or abscesses beyond the region of
vaccination [22].
4) Hepatosplenomegaly.
5) Bone tenderness or swelling reflecting underlying oste-
omyelitis [23,24].
6) Signs of meningeal involvement, such as seizures [20].3.2.2. Investigations for disseminated BCG infection
The investigations should be obtained with guidance of
pediatric immunology and infectious diseases specialists.
These may include identification of the M. bovis from the
patient’s organs by culture and/or standard PCR, as well as
typical histopathological changes with granulomatous
inflammation, in addition to identifying the specific un-
derlying immunodeficiency status. Radiological in-
vestigations such as bone scan and abdominal Computed
Tomography (CT) scan may be beneficial in evaluating the
site(s) and extent of dissemination.
4. Factors associated with increased BCG
lymphadenitis incidence
4.1. Vaccine related factors
1) Residual virulence of the BCG strain: BCG strains from
different pharmaceutical manufacturers are known to
have different reactogenicity profile [12,14,25,26].
2) Viability of final vaccine product: This is related to the
quality of the administered vaccine and is affected by
storage conditions such as the cold chain [14,25]. Live
particles concentration in the vaccines ranges from
50,000 to 3 million per dose, according to the BCG
strain [1].
4.2. Administration related factors
1) Subcutaneous injection: Subcutaneous administration
has been associated with a higher frequency of BCG
vaccine complications in comparison with correctly
administered intradermal injection [14,25].
2) Dose of BCG injection: The higher the dose of BCG in-
jection the more risk of developing vaccine adverse ef-
fects including lymphadenitis [14,25,27].
4.3. Host related factors
1) Age: neonates have a higher risk of regional lymphade-
nitis [14,25,26].
2) Immune status: Immunocompromised patients such as
those suffering from SCID or IFN-g/IL-12 pathway de-
fects, have increased rates of local complications as well
as disseminated BCG infection [12,14,21,28].
5. Management of BCG related lymphadenitis
5.1. Management of BCG related lymphadenitis
algorithm
92 N. Elsidig et al.i failed initial aspiration, failed repeated aspiration or re-
accumulation after 2 aspirations
ii persistent  6e9 months, with size 3 cm
5.2. Management of non-suppurative lymphadenitis
The non suppurative form is a relatively benign clinical
course where most of the nodes resolve spontaneouslywithin 4e6months. Antimycobacterial therapy generally
have no effect on the course [29], rather reassurance and
regular follow up are needed.
The following are recommended clues for the initial
assessment and subsequent evaluation with follow up visits:
1. Detailed clinical history to rule out immunodeficiency.
2. Growth and development assessment.
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4. Symptoms or signs of dissemination (e.g. distant
lymphadenopathy, hepatosplenomegaly, skin lesions
etc.)
5. Address family concerns and emphasize on importance
to proceed with vaccination schedule (unless specific
contraindications).
If the node(s) show no signs of regression and remained
persistently enlarged for more than 6e9 months with a size
of 3 cm or more, it is unlikely to regress spontaneously
[18,28,30,31], therefore surgical excision may be consid-
ered [16,29,31].
5.3. Management of suppurative lymphadenitis
5.3.1. Role of antimicrobial therapy
Antimycobacterial drugs cannot prevent suppuration nor
shorten the duration of healing, therefore are not recom-
mended [16,20,29,32].
Antibiotic therapy is indicated for treatment of pyogenic
lymphadenitis, as a result of secondary infection with
pyogenic bacteria such as Streptococcus pyogenes or
Staphylococcus aureus.
5.3.2. Needle aspiration
When suppurative BCG lymphadenitis left untreated, it will
progress to spontaneous rupture/drainage and sinus for-
mation. This leads to slow healing over several months and
probable keloid formation. Moreover, it is associated with
an unpleasant cosmetic outcome. In contrast, needle
aspiration can shorten the duration of healing, and lessens
the complications [8,14,16,29,30,33e36].
Sometimes repeated aspirations are required for optimal
management. For ease of evacuation of thick inflammatory
materials, a wider bore needles are preferred [35].
Needle aspiration is considered to be a safer option
when compared with surgical excision, which likely will
require general anesthesia in young infants. Incision and
drainage should be avoided due to the risk of persistent
draining wound, delayed wound healing and unpleasant
cosmetic outcome with scar formation [14,35,36].
Generally it’s not recommended to send the aspirated
fluid for bacterial or mycobacterial examination unless
expecting a pyogenic infection or suspecting an associ-
ated disseminated disease to help in antimicrobial
selection.
5.3.3. Surgical excision
Surgical excision should be considered for children who
failed needle aspiration or failed to respond to repeated
needle aspirations more than twice, after balancing the
risks of general anesthesia and potential surgical compli-
cations [14,16,33,36].
5.4. Management of disseminated BCG infection
5.4.1. Immunology workup to rule out immunodeficiency
and optimizing treatment
Health care provider should suspect immunodeficiency in
all cases with disseminated disease, therefore pediatricimmunology service should be consulted to rule out any
underlying immunodeficiency disease (e.g. SCID, CGD and
IFN-g/IL-12 pathway defects) and to help in optimizing
treatment of the underlying immunodeficiency status e.g.
Hematopoietic stem cell transplantation (HSCT) in patients
with SCID [28,37,38].
5.4.2. Antimycobacterial treatment
Antimycobacterial therapy should be started in consulta-
tion with pediatric infectious diseases specialists.
Which agents, number and duration of anti-
mycoabcetrial drugs depends on the microbiological sus-
ceptibility testing, underlying immunodeficiency, degree of
dissemination and clinical response. Generally a minimum
of four medications are required, with duration of therapy
vary from months to years depending on the response and
underlying immune defects.
M. bovis are intrinsically resistant to pyrazinamide. BCG
strains have different susceptibility patterns [39], an
example is the Danish strain (SSI 1331), currently used in
Saudi Arabia, have low-level resistance to isoniazid that
may not be of clinical significance [39,40] on the other hand
it is resistant to ethionamide [39]. These differences should
be taken into consideration when selecting empirical
therapy
6. Conclusions
1) Non suppuartive lymphadenitis is a clinical diagnosis that
requires close observation and follow-up. Anti-
mycobactrial therapy are not recommended while sur-
gical excision may be considered if the node remained
persistently enlarged more than 6e9 months with a size
of 3 cm or more.
2) Suppurative lymphadenitis is a clinical diagnosis that
requires needle aspiration while incision and drainage is
not recommended. Surgical excision is considered upon
failed aspiration(s). Sending aspirated fluid for microbi-
ological examination is generally not indicated unless
expecting a disseminated or pyogenic infection.
3) Disseminated BCG infection requires consultation with
pediatric immunology and infectious diseases specialists
for the optimum management.
4) Based on available data on the BCG vaccine with a low
efficacy, serious complications and the high incidence of
primary immunodeficiency disorders among Saudi chil-
dren, it is wise to consider delay the timing of BCG
vaccination in our community.References
[1] Observed Rate of Vaccine Reactions, Bacille Calmette Guerin
(BCG) Vaccine 2012. World Health Organization (WHO), Global
Vaccine Safety, Immunization, Vaccines and Biologicals.
[2] Mahmoud Refqi, Emam Fahmi. Childhood immunization pro-
gram, surveillance report. Qassim, Saudi Arabia: General
Directorate of Health Affairs, Qassim Region, Public Health
Administration; 2011.
[3] Andersen P, Doherty TM. The success and failure of BCG e
implications for a novel tuberculosis vaccine. Nat Rev Micro-
biol 2005 Aug;3(8):656e62.
94 N. Elsidig et al.[4] Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E,
Fineberg HV, et al. Efficacy of BCG vaccine in the prevention
of tuberculosis: meta-analysis of the published literature.
JAMA 1994;271:698e702.
[5] Expanding immunization coverage. Immunization, vaccines
and biological. WHO/UNICEF. [Updated 2014; Accessed 2014
September 4]. Available from URL: http://www.unicef.org/
immunization/index_coverage.html.
[6] World Health Organization (WHO) estimates of tuberculosis
incidence by country. 2013. http://www.hpa.org.uk/web/
HPAweb&HPAwebStandard/HPAweb_C/1195733758290.
[7] Lotte A, Wasz-Ho¨ckert O, Poisson N, Dumitrescu N, Verron M,
Couvet E. BCG complications. Adv Tuberc Res 1984;21:
107e93.
[8] Suliman OM, Ahmed MJ, Bilal JA. Clinical characteristics and
needle aspiration management of Bacillus Calmette-Gue´rin
lymphadenitis in children. Saudi Med J 2015 Mar;36(3):280e5.
http://dx.doi.org/10.15537/smj. 2015.3.10294.
[9] Ru Sorense. Clinical presentation of tuberculosis in patient
with immunodeficiency. Pediatr Infect Dis J 1989;8:201e6.
Annals of Pediatric Surgery, Vol 5, No 3, July 2009, PP
187e193.
[10] Grange JM. Complications of Bacille Calmette-Gue´rin (BCG)
vaccination and immunotherapy and their management.
Commun Dis Public Health 1998;1:84e8.
[11] Alrabiaah AA, Alsubaie SS, Bukhari EI, Gad A, Alzamel FA.
Outbreak of Bacille Calmette-Gue´rin-related lymphadenitis in
Saudi children at a university hospital after a change in the
strain of vaccine. Ann Saudi Med 2012 Jan-Feb;32(1):4e8.
PubMed PMID: 22156633.
[12] Al Jumaah Suliman, Al Hajjar Sami, Mousab Hamoud Al. Bacille
Calmette-Gue´rin vaccination in Saudi Arabia: benefits versus
risks. Ann Saudi Med 2012;32(1):1e3. http://dx.doi.org/
10.5144/0256-4947.2012.1. PMID: 22156632.
[13] Goraya JS, Virdi VS. Bacille Calmette-Gue´rin lymphadenitis.
Postgrad Med J 2002 Jun;78(920):327e9. PMCID: PMC1742390.
[14] Chan WM, Kwan YW, Leung CW. Management of Bacillus
Calmette-Gue´rin lymphadenitis. HK J Paediat 2011;16:85e94
(new series).
[15] Goraya JS, Virdi VS. Treatment of Calmette-Gue´rin bacillus
adenitis: a metaanalysis. Pediatr Infect Dis J 2001 Jun;20(6):
632e4. PubMed PMID: 11419511.
[16] Sataynarayana S, Mathur AD, Verma Y, Pradhan S,
Bhandari MK. Needle aspiration as a diagnostic tool and
therapeutic modality in suppurative lymphadenitis following
Bacillus Calmette Guerin vaccination. J Assoc Physicians India
2002 Jun;50:788e91. PubMed PMID: 12240843.
[17] Al-Salem AH, Kothari MR, AlHani HM, Oquaish MM, Khogeer SS,
Desouky MS. Safety of intradermal Bacillus Calmette-Guerin
vaccine for neonates in Eastern Saudi Arabia. Saudi Med J
2012 Feb;33(2):172e6. PubMed PMID: 22327758.
[18] Bukhari E, Alzahrani M, Alsubaie S, Alrabiaah A, Alzamil F.
Bacillus Calmette-Guerin lymphadenitis: a 6-year experience
in two Saudi hospitals. Indian J Pathol Microbiol 2012 Apr-Jun;
55(2):202e5. http://dx.doi.org/10.4103/0377-4929.97869.
PubMed PMID: 2277164.
[19] Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS,
et al. Bacille Calmette-Gue´rin vaccine-induced disease in HIV-
infected and HIV-uninfected children. Clin Infect Dis 2006;(42):
548e58. http://dx.doi.org/10.1086/499953. pmid: 16421800.
Infection. 1991 Nov-Dec; 19(6):414-6.
[20] Sohail Shagufta, Afzal Muhammad, Anwar Vaqas,
Shama Quratulain. Disseminated Bacille calmette e guerin
(BCG) disease in an infant with severe combined immunode-
ficiency: S259eS261. J Coll Physicians Surg Pak 2014;24.
[21] Galal N, Boutros J, Marsafy A, Kong XF, Feinberg J,
Casanova JL, et al. Mendelian susceptibility to mycobacterialdisease in egyptian children. Mediterr J Hematol Infect Dis
2012;4(1). e2012033.
[22] Gantzer A, Neven B, Picard C, Brousse N, Lortholary O,
Fraitag S, et al. Severe cutaneous bacillus Calmette-Gue´rin
infection in immunocompromised children: the relevance of
skin biopsy. J Cutan Pathol 2013;40(1):30e7.
[23] Oyachi N, Obana K, Suzuki T, Kimura S, Chino K, Oyama T,
et al. Costal BCG osteomyelitis developing 1 year after BCG
vaccination. Pediatr Int 2013 Oct;55(5):641e3. http:
//dx.doi.org/10.1111/ped.12072. PubMed PMID: 24134752.
[24] Chan PK, Ng BK, Wong CY. Bacille Calmette-Gue´rin osteomy-
elitis of the proximal femur. Hong Kong Med J 2010 Jun;16(3):
223e6. PubMed PMID: 20519760.
[25] Milstien JB, Gibson JJ. Quality control of BCG vaccine by
WHO: a review of factors that may influence vaccine
effectiveness and safety. Bull World Health Organ 1990;
68:93e108.
[26] Hengster P, Schnapka J, Fille M, Menardi G. Occurrence of
suppurative lymphadenitis after a change of BCG vaccine.
Arch Dis Child 1992;67:952e5.
[27] Ladeira I, Carvalho I, Correia A, Carvalho A, Duarte R. BCGitis
in children. Rev Port Pneumol 2014;20(3):172e3. Epub
2014/02/18.
[28] Ying W, Sun J, Liu D, Hui X, Yu Y, Wang J, et al. Clinical
characteristics and immunogenetics of BCGosis/BCGitis in
Chinese children: a 6 year follow-up study. PloS One 2014;
9(4):e94485. Epub 2014/04/12.
[29] Cuello-Garcı´a CA, Pe´rez-Gaxiola G, Jime´nez Gutie´rrez C.
Treating BCG-induced disease in children. Cochrane Database
Syst Rev 2013 Jan 31;1:CD008300. http://dx.doi.org/
10.1002/14651858.CD008300.pub2. Review. PubMed PMID:
23440826.
[30] Hassana Rasha H, Abel-Elah Alyb Kamal, Kandila Shaimaa M,
El Maysaa, Sayed Zaki. Post-Bacillus Calmette-Gue´ rin
lymphadenitis in Egyptian children: an outbreak. Ann Pediatr
Surg 2012;8:69e73.
[31] Daei Parizi M, Kardoust Parizi A, Izadipour S. Evaluating clin-
ical course of BCG lymphadenitis and factors affect on it
during a 5-year period in Kerman, Iran. J Trop Pediatr 2014;
60(2):148e53. Epub 2013/12/12.
[32] Nazir Z, Qazi SH. Bacillus Calmette-Guerin (BCG)
lymphadenitis-changing trends and management. J Ayub Med
Coll Abbottabad 2005 Oct-Dec;17(4):16e8. PubMed PMID:
16599027.
[33] Abdulhameed Fatma D, Hummaida Tarig I. Surgical manage-
ment of BCG vaccine e induced regional lymph nodes adverse
effects. Ann Pediatr Surg July 2009;5(3):187e93.
[34] Caglayan S, Arikan A, Yaprak I, Aksoz K, Kansoy S. Manage-
ment of suppuration in regional lymph nodes secondary to
BCG vaccination. Acta Paediatr Jpn 1991 Dec;33(6):
699e702.
[35] Juzi JT, Sidler D, Moore SW. Surgical management of BCG
vaccine-induced regional axillary lymphadenitis in HIV-
infected children. S Afr J Surg 2008 May;46(2):52e5. PubMed
PMID: 18686936.
[36] Pal Subrata, Chakarabarti1 Srabani, Prakash Phukan Jyoti,
Biswas Sudhanya, Sinha Anuradha, Sinha Rajani. Role of
needle aspiration in diagnosis and management of
suppurative Bacille CalmetteeGuerin adenitis: an institu-
tional study of 30 cases. J Laboratory Physicians Jan-Jun
2015;7(1).
[37] Roesler J, Horwitz ME, Picard C, Bordigoni P, Davies G,
Koscielniak E, et al. Hematopoietic stem cell transplantation
for complete IFN-gamma receptor 1 deficiency: a multi-
institutional survey. J Pediatr 2004;145(6):806e12.
[38] Shahmohammadi Soheila, Mohammad JS, Mohammad SR.
BCG-osis after BCG vaccination in immunocompromised
Bacillus CalmetteeGue´rin vaccine related lymphadenitis in children 95children: case series and review. J Pediatr Rev 2014;2(1):
47e54. http://dx.doi.org/10.7508/JPR-V2-N1-62-74.
[39] Ritz Nicole, Tebruegge Marc, Connell Tom G, Sievers Aina,
Robins-Browne Roy, Curtis Nigel. Susceptibility ofmycobacterium bovis BCG vaccine strains to antituberculous
antibiotics. Antimicrob Agents And Chemother Jan. 2009:
316e8. http://dx.doi.org/10.1128/AAC.01302-08.
[40] Description of BCG VACCINE SSI, www.ssi.dk.
